Inventiva Reports H1 2026 Cash of €234M, Extends Runway to Q2 2027 After June Refinancing
IVA sits 53% above its 52-week low of $2.94.
Summary
Inventiva reported preliminary H1 2026 financials with €234 million in cash and deposits, reflecting the June capital optimization. Cash runway extends to Q2 2027, or Q1 2028 with contingent capital, but the company still faces a going-concern risk.
Key Events · Earnings and Guidance · IVA
-
H1 2026 Cash Position
Cash and cash equivalents of €166.1 million and short-term deposits of €67.8 million as of June 30, 2026, compared to €99.3 million and €131.6 million at year-end 2025.
-
Cash Burn and Runway
Net cash used in operations was €48.7 million in H1 2026. Existing resources fund operations into Q2 2027; with Tranche C debt (up to €20M) and full warrant exercise (up to €116M), runway extends to early Q1 2028.
-
June Refinancing Impact
Financing activities generated €50.9 million, driven by the €103 million equity offering and €75 million debt transaction, partially offset by €62 million EIB loan repayment and €50 million warrant repurchase.
-
Going Concern Risk
Current cash and equivalents are not sufficient to cover operating needs for the next 12 months; the company remains dependent on additional financing or contingent capital to continue as a going concern.
Analysis · IVA · Life Sciences
Inventiva disclosed preliminary first-half 2026 results, showing €166.1 million in cash and €67.8 million in short-term deposits as of June 30, 2026. The company burned €48.7 million in operations, offset by €63.9 million from investing and €50.9 million from financing — the latter reflecting the June 2026 capital overhaul that included a €103 million equity offering and €75 million debt transaction. Management now expects existing resources to fund operations into the second quarter of 2027, or into early 2028 if contingent capital (Tranche C debt and warrant exercises) materializes. The update confirms the company remains in a going-concern posture — current cash alone does not cover the next 12 months — but the runway extension from the June deals provides breathing room as the pivotal NATiV3 trial advances.
At the time of this filing, IVA was trading at $4.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.94 to $7.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.